Physician profile
Daniel Hernandez
NPI 1457394512
$1,309.70
in general payments reported to CMS, 2019-2025
13 companies · $738 in 2025
The $738 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $572 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,309.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $386.36 | 2024-2025 | Relistor |
| Radius Health, INC. | $232.67 | 2024-2025 | Tymlos |
| Abbvie INC. | $201.67 | 2024-2025 | |
| Globus Medical, INC. | $169.61 | 2025 | Senza |
| Saluda Medical Americas, INC. | $88.41 | 2024-2025 | Evoke |
| Painteq LLC | $44.14 | 2024 | Painteq |
| Azurity Pharmaceuticals, INC. | $35.13 | 2024 | Horizant |
| Valinor Pharma, LLC | $34.76 | 2025 | Movantik |
| Nevro Corp. | $27.68 | 2024 | Senza |
| Amgen INC. | $24.49 | 2025 | Evenity |
| Nalu Medical, INC. | $24.41 | 2025 | Nalu Neurostimulation System |
| Bioventus LLC | $23.62 | 2025 | Xcell |
| Pfizer INC. | $16.75 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.